

## **Cipla acquires stake in Clean Max Auriga Power LLP; progresses towards championing its ESG agenda**

**Mumbai, India; December 15, 2021:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has acquired up to 33% of partnership interest in Clean Max Auriga Power LLP (Limited Liability Partnership). This agreement is in line with the Company's commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a captive user under electricity laws.

Clean Max Auriga Power LLP is a special purpose vehicle engaged in the business of production, supply and distribution of solar and wind or other renewable energy generation plant. The Company was incorporated on 18<sup>th</sup> February 2019 and was formed for the purpose of setting up captive wind and solar, renewable power generation plant (Project) in Karnataka.

**Mr. Kedar Upadhye, President & Global CFO, Cipla**, said, "ESG is at the centre of focus at Cipla and with this acquisition we are progressing on the right track of being purposeful by embedding sustainability into our businesses. It is a testament to our commitment of using cleaner, renewable sources of energy and it fuels our ambition of enabling a greener environment"

Commenting on the development, **Ms. Geena Malhotra, Global Chief Technology Officer who spearheads Cipla's ESG agenda** said, "This acquisition is in line with our steady efforts towards progressing on goals that we have set out to achieve in the ESG space. Sustainability is at the core of Cipla and while we have miles to go in this path that we have undertaken to achieve our ESG goals, we are gradually moving towards it through such acquisitions and partnerships."

### **About Cipla:**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT October 2021), 3rd largest in the pharma private market in South Africa (IQVIA MAT October 2021), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com), or click on Twitter, Facebook, LinkedIn.

**For queries, please contact**

**Corporate Communications**

Heena Kanal

E-Mail: [CorpComm@cipla.com](mailto:CorpComm@cipla.com)